AI assistant
Sending…
PLUS THERAPEUTICS, INC. — Director's Dealing 2017
Jan 27, 2017
34301_dirs_2017-01-27_aac56bb5-ec88-4108-9be3-240c542c7f20.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CYTORI THERAPEUTICS, INC. (CTYX)
CIK: 0001095981
Period of Report: 2017-01-26
Reporting Person: LYONS GARY A (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-01-26 | Non-Qualified Stock Option (right to buy) | $1.56 | A | 25000 | Acquired | 2027-01-26 | Common Stock (25000) | Direct |
Footnotes
F1: The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price on the date of the grant was $1.56.
More from PLUS THERAPEUTICS, INC.
Capital/Financing Update
2026
Jun 5
Regulatory Filings
2026
Jun 5
Capital/Financing Update
2026
Jun 1
Declaration of Voting Results & Voting Rights Announcements
2026
May 15
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Regulatory Filings
2026
Apr 21
Board/Management Information
2026
Apr 9
Regulatory Filings
2026
Apr 8
Board/Management Information
2026
Mar 26